RecruitingNeoplasms, Prostate
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Eligible age
18+ yrs
Accepts
Men
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
Sponsor: GlaxoSmithKline
You may qualify if…
- ✓ Participants with mCRPC that have histologically or cytologically confirmed adenocarcinoma of the prostate.
- ✓ Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT).
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 and life expectancy of ≥3 months (≥12 weeks).
- ✓ Progression on ADT and \>=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC) and received 1-2 prior taxane-based chemotherapy regimens. Participants should have received all approved standard-of-care therapies for which they are eligible, including biomarker directed therapy, in accordance with current clinical guidelines, unless a documented contraindication or another justified medical reason precluded their use.
You may not qualify if…
- ✕ Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate, or any histology different from adenocarcinoma.
- ✕ Impaired cardiac function or clinically significant cardiac disease.
- ✕ Any significant medical condition, such as uncontrolled infection or clinically significant laboratory abnormality.
- ✕ Prior therapy with Androgen receptor (AR) Degrader targeted therapy. Other protocol-defined inclusion/exclusion criteria apply.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07332455 · last updated 2026-11-09